Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)-Reference-Cited by-同舟云学术

Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)

Published:2024-02 Issue:2 Volume:43 Page:272-283
ISSN:1053-2498
Container-title:The Journal of Heart and Lung Transplantation
language:en
Short-container-title:The Journal of Heart and Lung Transplantation

Author:

McLaughlin Vallerie,Farber Harrison W.,Highland Kristin B.,Hemnes Anna R.,Chakinala Murali M.,Chin Kelly M.,Han Michelle^ORCID,Cho Michelle,Tobore Tobore^ORCID,Rahman Mohammad,Kim Nick H.

Funder

Actelion Pharmaceuticals

Publisher

Elsevier BV

Subject

Transplantation,Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference30 articles.

1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension;Humbert;Eur Heart J,2022

2. Pulmonary arterial hypertension in France: results from a national registry;Humbert;Am J Respir Crit Care Med,2006

3. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era;Humbert;Circulation,2010

4. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation;Thenappan;Eur Respir J,2010

5. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era;Launay;Ann Rheum Dis,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study);Advances in Therapy;2024-07-31

2. Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension;Pulmonary Circulation;2024-07

3. Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy;The Journal of Rheumatology;2024-06-15

4. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag;Journal of Patient-Reported Outcomes;2023-12-18